Nanoligent
PrivateLast Round
Series A
Oct 6, 2025
Total Funding Raised
$16.59M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
Nanoligent is a biotechnology company that develops nanotechnology-based anti-cancer treatments intended to treat different types of metastatic cancer.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Nanoligent Comparables
Compare Nanoligent with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Mainline Biosciences | 78% | |
| Cybrexa Therapeutics | 76% | |
| Polar NanoPharma | 76% | |
Nanoligent Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Oct 6, 2025 | ||||
| Grant | Jun 19, 2025 | ||||
| Accelerator | Nov 21, 2023 | ||||
| Seed | Sep 27, 2022 | ||||
| Grant | Dec 13, 2018 |
Key People
Founding team and executive leadership
Nanoligent Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Inveready | Series A |
| Avanteca Partners | Seed, Series A |
| Clave Capital | Series A |
| Center for Technological Development and Innovation | Series A |
| i&i Prague | Seed |
| Doorway | Seed, Series A |
| Italian Angels for Growth | Seed, Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Apr 18, 2026
Monthly visitors grew 243% MoM.
- Jun 19, 2025
Won the Santander X Award 2025 for Best University Start-up.
Nanoligent Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Nanoligent's valuation, stock price, and market status.